Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Akebia Therapeutics Inc’s stock clocked out at $2.55, up 6.25% from its previous closing price of $2.40. In other words, the price has increased by $6.25 from its previous closing price. On the day, 4.97 million shares were traded. AKBA stock price reached its highest trading level at $2.58 during the session, while it also had its lowest trading level at $2.328.
Ratios:
To gain a deeper understanding of AKBA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.21 and its Current Ratio is at 1.41.
On August 28, 2023, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $3.75.
Piper Sandler Upgraded its Neutral to Overweight on May 31, 2023, whereas the target price for the stock was revised from $2 to $4.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 03 ’25 when Butler John P. sold 46,409 shares for $1.83 per share. The transaction valued at 84,928 led to the insider holds 2,557,921 shares of the business.
Burke Steven Keith sold 7,144 shares of AKBA for $13,074 on Mar 03 ’25. The SVP, Chief Medical Officer now owns 809,090 shares after completing the transaction at $1.83 per share. On Mar 03 ’25, another insider, Burke Steven Keith, who serves as the Officer of the company, bought 7,144 shares for $1.83 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 602389056 and an Enterprise Value of 739248192. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.76. Its current Enterprise Value per Revenue stands at 4.615 whereas that against EBITDA is -84.952.
Stock Price History:
The Beta on a monthly basis for AKBA is 0.76, which has changed by 0.31443298 over the last 52 weeks, in comparison to a change of 0.07465422 over the same period for the S&P500. Over the past 52 weeks, AKBA has reached a high of $2.48, while it has fallen to a 52-week low of $0.80. The 50-Day Moving Average of the stock is 25.14%, while the 200-Day Moving Average is calculated to be 58.28%.
Shares Statistics:
It appears that AKBA traded 2.63M shares on average per day over the past three months and 4780660 shares per day over the past ten days. A total of 236.23M shares are outstanding, with a floating share count of 226.53M. Insiders hold about 4.10% of the company’s shares, while institutions hold 26.51% stake in the company. Shares short for AKBA as of 1740700800 were 14879018 with a Short Ratio of 5.66, compared to 1738281600 on 14453171. Therefore, it implies a Short% of Shares Outstanding of 14879018 and a Short% of Float of 6.890000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
